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Over recent years, human papillomavirus
(HPV) has been shown to be a major risk
factor for head and neck squamous cell
cancer (HNSCC), and particularly oro-
pharyngeal squamous cell carcinoma.1 2
In 2007, the International Agency for
Research on Cancer recognised HPV as a
carcinogen associated with malignant
transformation in this subset of head and
neck cancers. It is now well established
that HPV-induced oropharyngeal cancers
and those caused by other factors (such as
smoking and alcohol abuse—a combin-
ation of heavy smoking and drinking
leads to an almost 50-fold increased risk
of oral and pharyngeal cancer3) are two
separate entities, with distinct aetiologies,
clinical characteristics, prognoses and a
different epidemiology and molecular
basis.4
The incidence of HPV-associated
HNSCC has risen rapidly in the Western
world over the past 40 years.5–8 For
example, there has been an estimated
threefold increase in tonsillar cancer
during this period,9 and the overall esti-
mated population-level incidence of
HPV-positive oropharyngeal cancer,
which was 2.6 per 100 000 in the USA in
2004,6 is set to triple again in the next
20 years.10 Interestingly, the overall inci-
dence of HNSCC is falling at a time when
the incidence of HPV-induced cancer has
risen, with the result that the proportion
of HPV-positive tonsillar cases has risen
from <25% in the 1970s to 93% of cases
by 2007 in parts of the developed world.7
It is also noteworthy that those affected
tend to be younger patients (age
<50 years) who are frequently non-
smokers, and that men seem to be at
higher risk of developing this type of
cancer than women.11
There is good evidence for sexual
acquisition of oropharyngeal HPV infec-
tion,12 13 and an intriguing hypothesis is
that the increase in HPV-associated
HNSCC might be driven in part and pre-
dated by changes in population sexual
behaviour. In the UK, for example, a sig-
niﬁcant increase in the proportion of
people reporting oral sex in the past year
occurred between 1990 and 2000, and
this proportion remained high between
2000 and 2010.14 Similarly, around 75%
of men and 65% of women born between
1946 and 1955 reported ever giving or
receiving oral sex, but this proportion was
over 90% among men and women born
20 years later. That oral sex is an almost
ubiquitous exposure probably explains
why some of the largest and methodo-
logically most robust studies have failed to
ﬁnd an association between reporting oral
sex and the detection of oral HPV infec-
tion.15 However, much remains to be
understood about the acquisition and per-
sistence of oral HPV infection, and the
evidence for changes in sexual behaviour
driving increases in HPV-associated
HNSCCs is still circumstantial.
The increase in HPV-induced HNSCC
has important clinical implications because
this subset of cancers responds better to
chemotherapy and radiotherapy (82% vs
55% response rate for HPV-negative cases)
and has a better disease-free and overall
survival (95% vs 62% at 2 years).16
Patients with HPV-induced HNSCC have
a lower incidence of second primary
tumours, as well as decreased risk (or
cumulative incidence) of relapse.17 18
In the same way that HPV testing has
been incorporated into the cervical cancer
screening programme for samples with
borderline or mild dyskaryosis to inform
clinical management,19 there is now inter-
est in developing a valid and reliable test to
determine the HPV status of oropharyn-
geal tumours. This may enable risk stratiﬁ-
cation of patients to inform treatment
decisions, as well as further elucidating the
molecular virology and mechanisms
underlying the advantage in drug response
and survival seen in HPV-associated
HNSCC. In order to do this, one needs to
better understand how HPV-induced oro-
pharyngeal cancers evolve. It is well estab-
lished that cervical cancer develops
through increasingly severe grades of neo-
plasia, and understanding of the sequence
of molecular changes underlying these
events has supported implementation of
screening programmes, which in turn have
signiﬁcantly reduced the mortality of cer-
vical cancer in the Western world.20 Anal
and penile carcinogenesis are also increas-
ingly well described, with >80% of anal
cancers21 and around 40% of penile
cancers being HPV-associated. However,
for oropharyngeal cancers, the equivalent
precancerous lesions have yet to be
deﬁned. Good understanding of the transi-
tion from a transient to persistent HPV
infection and then to cancer is also
lacking, and a biomarker that would
enable risk assessment of lesions to distin-
guish malignancy potential does not exist.
There is increasing evidence that the risk
of HPV-associated malignancies, such as
anal and penile cancer, is higher in
HIV-infected individuals and men who
have sex with men (MSM).22 If the risk of
HNSCC is similarly increased in these
groups (and a recent study has shown a
higher incidence of HPV-associated
HNSCCs among HIV-positive indivi-
duals23), these groups may stand to beneﬁt
most from any screening programme.
Although the effectiveness of HPV vac-
cination to protect against head and neck
cancers is not yet proven, in some case
series >70% of oropharyngeal cancers test
positive for high-risk HPV type-16.1
Immunisation against oncogenic HPV sub-
types, introduced in the UK for girls in
2008, is likely to transform the epidemi-
ology of all HPV-associated cancers in the
UK and in other countries where it has
been introduced. Dramatic changes in the
incidence of HPV-associated cancers are
therefore to be expected. There are also
several proposed changes to vaccination
programmes that may further affect the
incidence of HPV-associated cancers. A
nonavalent vaccine is currently in clinical
trials, which would protect against high-risk
HPV types not included in the current vac-
cines (Gardasil and Cervarix protect against
HPV 16 and 18 and not HPV 31 and 33).
In the UK, the decision not to vaccinate
boys is being revisited by the Joint
Committee on Vaccination and
Immunisation, in part due to increasing evi-
dence about the role of HPV in anal,
penile, head and neck, and other cancers,
and in part due to the lack of herd protec-
tion afforded to MSM. However, indivi-
duals currently infected with high-risk HPV
in the oropharynx and the vast majority of
the global population who have not been
vaccinated remain at risk of developing
HPV-associated head and neck cancer.
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